Financhill
Sell
28

WST Quote, Financials, Valuation and Earnings

Last price:
$223.81
Seasonality move :
7.42%
Day range:
$219.76 - $224.75
52-week range:
$197.01 - $397.72
Dividend yield:
0.37%
P/E ratio:
33.21x
P/S ratio:
5.66x
P/B ratio:
5.99x
Volume:
495.7K
Avg. volume:
1.3M
1-year change:
-43.85%
Market cap:
$16.1B
Revenue:
$2.9B
EPS (TTM):
$6.69

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
WST
West Pharmaceutical Services
$685.2M $1.23 -1.46% -20.37% $285.01
BAX
Baxter International
$2.6B $0.48 -27.97% 590.29% $40.05
BDX
Becton Dickinson &
$5.4B $3.28 6.1% 77.32% $276.57
RMD
ResMed
$1.3B $2.36 7.21% 15.65% $270.09
TFX
Teleflex
$705.9M $2.95 -4.26% 825.78% $168.21
UFPT
UFP Technologies
$139.9M $2.01 33.42% 21.75% $381.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
WST
West Pharmaceutical Services
$222.20 $285.01 $16.1B 33.21x $0.21 0.37% 5.66x
BAX
Baxter International
$33.75 $40.05 $17.3B 167.20x $0.17 2.73% 1.34x
BDX
Becton Dickinson &
$227.50 $276.57 $65.3B 37.79x $1.04 1.75% 3.20x
RMD
ResMed
$219.94 $270.09 $32.3B 25.97x $0.53 0.94% 6.59x
TFX
Teleflex
$137.80 $168.21 $6.4B 97.04x $0.34 0.99% 2.13x
UFPT
UFP Technologies
$199.32 $381.00 $1.5B 26.23x $0.00 0% 3.07x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
WST
West Pharmaceutical Services
7.02% 1.553 0.92% 1.88x
BAX
Baxter International
65.34% 0.281 88.33% 0.54x
BDX
Becton Dickinson &
42.67% 0.476 28.8% 0.44x
RMD
ResMed
11.35% 0.169 2% 1.74x
TFX
Teleflex
27.91% 1.867 20.11% 1.15x
UFPT
UFP Technologies
35.59% 5.099 10.09% 1.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
WST
West Pharmaceutical Services
$273.6M $169.8M 16.88% 18.15% 21.92% $85.2M
BAX
Baxter International
$959M -$1M -3.07% -8.24% -15.29% $351M
BDX
Becton Dickinson &
$2.2B $546M 3.92% 6.75% 8.92% $588M
RMD
ResMed
$751.3M $417.2M 21.74% 25.56% 32.54% $285.2M
TFX
Teleflex
$439.9M $140.8M 1.13% 1.57% -13.59% $170.4M
UFPT
UFP Technologies
$42.1M $23.4M 14.28% 18.87% 15.6% $21.4M

West Pharmaceutical Services vs. Competitors

  • Which has Higher Returns WST or BAX?

    Baxter International has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of -18.6%. West Pharmaceutical Services's return on equity of 18.15% beat Baxter International's return on equity of -8.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
    BAX
    Baxter International
    34.84% -$1.00 $20.2B
  • What do Analysts Say About WST or BAX?

    West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 28.27%. On the other hand Baxter International has an analysts' consensus of $40.05 which suggests that it could grow by 18.67%. Given that West Pharmaceutical Services has higher upside potential than Baxter International, analysts believe West Pharmaceutical Services is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    8 2 0
    BAX
    Baxter International
    3 11 1
  • Is WST or BAX More Risky?

    West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison Baxter International has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.

  • Which is a Better Dividend Stock WST or BAX?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Baxter International offers a yield of 2.73% to investors and pays a quarterly dividend of $0.17 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or BAX?

    West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Baxter International quarterly revenues of $2.8B. West Pharmaceutical Services's net income of $130.1M is higher than Baxter International's net income of -$512M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.21x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.66x versus 1.34x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.66x 33.21x $748.8M $130.1M
    BAX
    Baxter International
    1.34x 167.20x $2.8B -$512M
  • Which has Higher Returns WST or BDX?

    Becton Dickinson & has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 5.86%. West Pharmaceutical Services's return on equity of 18.15% beat Becton Dickinson &'s return on equity of 6.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
    BDX
    Becton Dickinson &
    43.25% $1.04 $44B
  • What do Analysts Say About WST or BDX?

    West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 28.27%. On the other hand Becton Dickinson & has an analysts' consensus of $276.57 which suggests that it could grow by 21.57%. Given that West Pharmaceutical Services has higher upside potential than Becton Dickinson &, analysts believe West Pharmaceutical Services is more attractive than Becton Dickinson &.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    8 2 0
    BDX
    Becton Dickinson &
    7 4 0
  • Is WST or BDX More Risky?

    West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.526%.

  • Which is a Better Dividend Stock WST or BDX?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Becton Dickinson & offers a yield of 1.75% to investors and pays a quarterly dividend of $1.04 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or BDX?

    West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. West Pharmaceutical Services's net income of $130.1M is lower than Becton Dickinson &'s net income of $303M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.21x while Becton Dickinson &'s PE ratio is 37.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.66x versus 3.20x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.66x 33.21x $748.8M $130.1M
    BDX
    Becton Dickinson &
    3.20x 37.79x $5.2B $303M
  • Which has Higher Returns WST or RMD?

    ResMed has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 26.88%. West Pharmaceutical Services's return on equity of 18.15% beat ResMed's return on equity of 25.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
    RMD
    ResMed
    58.6% $2.34 $5.9B
  • What do Analysts Say About WST or RMD?

    West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 28.27%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 22.8%. Given that West Pharmaceutical Services has higher upside potential than ResMed, analysts believe West Pharmaceutical Services is more attractive than ResMed.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    8 2 0
    RMD
    ResMed
    8 6 1
  • Is WST or RMD More Risky?

    West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

  • Which is a Better Dividend Stock WST or RMD?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or RMD?

    West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than ResMed quarterly revenues of $1.3B. West Pharmaceutical Services's net income of $130.1M is lower than ResMed's net income of $344.6M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.21x while ResMed's PE ratio is 25.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.66x versus 6.59x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.66x 33.21x $748.8M $130.1M
    RMD
    ResMed
    6.59x 25.97x $1.3B $344.6M
  • Which has Higher Returns WST or TFX?

    Teleflex has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of -17.18%. West Pharmaceutical Services's return on equity of 18.15% beat Teleflex's return on equity of 1.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
    TFX
    Teleflex
    55.31% -$2.95 $5.9B
  • What do Analysts Say About WST or TFX?

    West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 28.27%. On the other hand Teleflex has an analysts' consensus of $168.21 which suggests that it could grow by 22.07%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    8 2 0
    TFX
    Teleflex
    0 11 0
  • Is WST or TFX More Risky?

    West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison Teleflex has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.134%.

  • Which is a Better Dividend Stock WST or TFX?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Teleflex offers a yield of 0.99% to investors and pays a quarterly dividend of $0.34 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or TFX?

    West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Teleflex quarterly revenues of $795.4M. West Pharmaceutical Services's net income of $130.1M is higher than Teleflex's net income of -$136.7M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.21x while Teleflex's PE ratio is 97.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.66x versus 2.13x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.66x 33.21x $748.8M $130.1M
    TFX
    Teleflex
    2.13x 97.04x $795.4M -$136.7M
  • Which has Higher Returns WST or UFPT?

    UFP Technologies has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 11.37%. West Pharmaceutical Services's return on equity of 18.15% beat UFP Technologies's return on equity of 18.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
    UFPT
    UFP Technologies
    29.19% $2.10 $532.1M
  • What do Analysts Say About WST or UFPT?

    West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 28.27%. On the other hand UFP Technologies has an analysts' consensus of $381.00 which suggests that it could grow by 91.15%. Given that UFP Technologies has higher upside potential than West Pharmaceutical Services, analysts believe UFP Technologies is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    8 2 0
    UFPT
    UFP Technologies
    1 2 0
  • Is WST or UFPT More Risky?

    West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.147, suggesting its more volatile than the S&P 500 by 14.692%.

  • Which is a Better Dividend Stock WST or UFPT?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or UFPT?

    West Pharmaceutical Services quarterly revenues are $748.8M, which are larger than UFP Technologies quarterly revenues of $144.1M. West Pharmaceutical Services's net income of $130.1M is higher than UFP Technologies's net income of $16.4M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.21x while UFP Technologies's PE ratio is 26.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.66x versus 3.07x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.66x 33.21x $748.8M $130.1M
    UFPT
    UFP Technologies
    3.07x 26.23x $144.1M $16.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Could IBIT Go?
How High Could IBIT Go?

Recently, a surprising number of billionaire hedge fund managers have…

Is Raymond James Stock a Buy, Sell or Hold?
Is Raymond James Stock a Buy, Sell or Hold?

Raymond James Financial (NYSE:RJF) is one of America’s large financial…

Is JHX Stock a Buy Sell or Hold?
Is JHX Stock a Buy Sell or Hold?

James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
41
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
78
AJINY alert for Mar 31

Ajinomoto [AJINY] is down 2.15% over the past day.

Sell
40
RGC alert for Mar 31

Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.

Buy
69
AGX alert for Mar 31

Argan [AGX] is down 4.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock